Drugs in ATC Class S01BA

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S01 - OPHTHALMOLOGICALS

Up to S01B - ANTIINFLAMMATORY AGENTS

Drugs in ATC Class: S01BA - Corticosteroids, plain

Tradename	Generic Name
CIPRODEX	ciprofloxacin; dexamethasone
CIPROFLOXACIN AND DEXAMETHASONE	ciprofloxacin; dexamethasone
AEROSEB-DEX	dexamethasone
DECASPRAY	dexamethasone

Market dynamics and patent landscape for ATC Class S01BA (plain corticosteroids)

Last updated: July 23, 2026

ATC S01BA (plain corticosteroids) is a dense, long-tail ophthalmic category with frequent reformulations (esters, salts, and combinations limited to “plain” steroids) and periodic exclusivity resets tied to formulation changes, device/packaging, and controlled-substance or preservative systems. Patent enforcement is generally fragmented by molecule and by jurisdiction, with most originator exclusivity already past in many markets. The competitive pressure comes from (1) high generic penetration, (2) patent “evergreening” via new concentrations and preservative systems, and (3) litigation that tends to cluster around specific formulation patents and manufacturing methods rather than around the base pharmacophores.

Which plain corticosteroid eye drops dominate ATC S01BA and how do they move volume?

Featured snippet answer: ATC S01BA “plain corticosteroids” is typically led commercially by acetate/prednisolone-class and related steroid formulations (for example prednisolone acetate), with competition from generic equivalents and, in some markets, newer prodrugs/esters that improve tolerability or dosing convenience.

What are the common actives and how do they map to “plain” vs “combo” products?

S01BA is “corticosteroids, plain.” This excludes steroid-antibiotic and steroid-NSAID combinations that sit in adjacent ATC groups. The practical implication for IP is that the “plain” category is narrower at the label level, but reformulation patents still compete on excipients, particle size, salt/ester selection, and viscosity/pH specs.

Typical “plain corticosteroid” ophthalmics in the S01BA universe include:

• Prednisolone acetate (often the historical anchor)
• Fluorometholone (where present in the market mix)
• Dexamethasone derivatives are more often classified under other ATC steroid groupings depending on exact label classification and jurisdiction-specific ATC assignment
• Loteprednol and etabonate derivatives frequently appear in ophthalmic steroid markets, though ATC assignment can vary by exact classification in local systems; some “steroid” prodrugs appear outside the “plain” subset depending on the listing schema.

Because ATC coding is not a patent boundary, many patent estates straddle multiple ATC codes when products are relabeled or repositioned. For an IP view, molecule-by-molecule is required.

How do patient and prescriber dynamics affect entry timing?

S01BA products are used for inflammatory conditions such as postoperative inflammation and noninfectious anterior segment inflammation. Market dynamics are driven by:

• Strong prescriber switching tolerance between equivalent steroid drops (if no meaningful difference in comfort and dosing)
• Pharmacy substitution and payer-driven generic selection
• Short treatment courses for many indications, which compress brand lifetime unless a distinct clinical/dosing advantage persists

What patents protect plain ophthalmic corticosteroids (S01BA) and how many are typically enforceable?

Featured snippet answer: The enforceable patent estate for S01BA products is usually concentrated in formulation patents (specific compositions, preservative systems, particle size/solid form), dosing/concentration patents, and manufacturing/method-of-use patents for specific inflammatory indications. Composition-of-matter patents on the active often expired first, leaving secondary patents as the main barrier for generic entrants.

What patent families typically appear across S01BA molecules?

Most patent landscapes for plain ophthalmic corticosteroids cluster into these buckets:

1. Formulation composition patents

   • Specific corticosteroid concentration ranges (e.g., 0.1%, 0.25%)
   • Preservative system (benzalkonium chloride vs alternative preservatives, preservative-free vials)
   • Buffer type, pH target, ionic strength, tonicity agents
   • Viscosity modifiers and suspending agents to improve residence time and reduce settling

2. Particle and solid-state patents

   • Particle size distribution for suspensions
   • Polymorph/crystal form or solvate specifications
   • Milling and homogenization method parameters to stabilize suspension

3. Manufacturing method patents

   • Sterile manufacture steps, milling/dispersion protocols
   • Sterilization method compatibility
   • In-process controls tied to acceptable specs

4. Method-of-use patents

   • Specific ophthalmic inflammatory indications (postoperative pain/inflammation, uveitis subtypes, allergic conjunctivitis when categorized)
   • Specific dosing regimens (frequency, taper schedule)
   • Specific patient populations in certain jurisdictions

5. Device/packaging patents

   • Unit-dose systems, preservative-free containers
   • Dropper design and delivery system patents
   • Some markets treat delivery systems as key differentiators when preservative-free is valued

How do patent “evergreening” patterns show up?

Common evergreening events in S01BA include:

• Moving from preserved multidose to preservative-free unit-dose, with new formulation and packaging patents.
• Introducing new strengths and dosing frequency regimens tied to method-of-use or formulation composition patents.
• Releasing “improved suspension stability” products with patents on particle size and manufacturing.

In practice, the “base drug” often lacks active composition-of-matter protection at the time generic entry occurs, shifting litigation to secondary patents.

When does exclusivity end for plain ophthalmic corticosteroids, and what windows matter?

Featured snippet answer: For most legacy S01BA products, generic entry is driven less by new U.S. exclusivity and more by patent expiration and any remaining regulatory exclusivities. In newer entrants or reformulations, data exclusivity and patent term adjustments create staggered launch timelines.

What exclusivity concepts move the schedule?

In the U.S. framework that most strongly governs paragraph IV risk:

• Orange Book patent expiration (including listed patents and any pediatric exclusivity extensions where applicable)
• 5-year data exclusivity / 3-year exclusivity (for certain new drug approvals or supplemental approvals) can delay generic approval if a new NDA/BLA relies on exclusivity-protected data
• Patent term adjustments (PTA) can push patent expiry later than statutory terms
• Pediatric exclusivity can add 6 months to eligible patents

In EU and other markets, the key dynamics are often:

• SPC (Supplementary Protection Certificates) tied to a marketing authorization
• Data exclusivity periods depending on member state and product status
• Regulatory protection around new formulations (where they constitute a new marketing authorization rather than a mere variation)

Where are the typical “launch gates”?

• U.S.: generic application can be submitted before expiration under ANDA rules if patents are listed; marketing depends on outcome of any litigation-triggered 30-month stay and final resolution.
• EU: entry can be blocked by SPCs and national patent injunctions.
• UK: similar to EU dynamics historically, with local enforcement differences.

Which patents are most often asserted in S01BA generic challenges (Paragraph IV)?

Featured snippet answer: In ophthalmic corticosteroids, paragraph IV litigation typically asserts secondary patents: formulation (composition) and method-of-manufacture patents, with method-of-use claims sometimes asserted where the generic carve-out or label includes disputed dosing regimens.

What litigation patterns appear by patent type?

• Formulation composition patents: most common, because they map to ANDA generic product specifications and stability.
• Method-of-use: asserted when generic label attempts to match branded indications or dosing schedules.
• Manufacturing methods: asserted when the brand alleges that generic manufacturing cannot meet the same particle size distribution or suspension stability specs.

What is the typical settlement structure?

Settlement agreements in ophthalmic generics often include:

• Delayed launch dates linked to patent expiry or risk-adjusted “design around” plans
• License or covenant-not-to-sue arrangements for specific dosage strengths and/or preservative formats
• Label carve-outs to avoid method-of-use infringement
• Sometimes a noninfringement strategy that leads to a “launch then narrow” behavior rather than a full settlement

What is the Orange Book status of the leading S01BA plain corticosteroid products?

Featured snippet answer: Many widely sold S01BA corticosteroids have Orange Book listing histories that show a move from primary active patents into secondary formulation and method patents. For legacy products, Orange Book listings often cluster at older filing dates and show limited remaining term.

How to interpret Orange Book listings for strategy?

For business and litigation planning, the Orange Book list should be treated as:

• A map of enforceable patents that can trigger ANDA litigation stays
• A proxy for where the brand has investable “defensibility” left

Practically:

• If few formulation patents remain, generic launch risk decreases.
• If multiple formulation patents are listed with different claim scopes, the generic faces a higher injunction probability.

(Orange Book status is product-specific; an ATC-level summary cannot substitute for molecule- and NDA-specific listing review.)

How strong is the patent estate for S01BA “plain corticosteroids” across jurisdictions?

Featured snippet answer: Patent strength in S01BA is typically strongest in formulation/particle-size domains with multiple overlapping secondary patents, but overall category risk is high because many actives are mature and enforcement windows are largely exhausted.

Jurisdictional differences that matter for enforcement

• U.S.: injunction leverage is tied to listed Orange Book patents and the litigation record; secondary formulation patents are often the battleground.
• EU: SPCs and national patents create stronger blocking power if still in force; reformulations that got new marketing authorizations can extend practical protection through follow-on rights.
• UK and other markets: enforcement depends on local patent validity and litigation throughput; smaller estates may reduce injunction likelihood.

How many “live” patents usually remain at the end of active-drug lifecycles?

In mature ophthalmic steroid markets, it is common to see:

• 1–3 formulation families per marketed strength still active in at least one jurisdiction
• additional process patents that are harder for generics to “copy around”
• method-of-use patents whose enforceability depends on label alignment and claim construction

What generic entry risks exist for S01BA plain corticosteroids?

Featured snippet answer: Generic entry risk is driven by (1) whether Orange Book patents still protect the exact strength/preservative/device format and (2) whether the generic label and formulation specs match the patented equivalents closely enough to create infringement arguments.

What creates the highest risk for generic applicants?

• Exact strength and pH/buffer match to branded specifications
• Preservative system replication where brand patents target stability
• Particle size specifications that mimic the branded suspension
• Method-of-use alignment that tracks patented dosing regimens

What creates the lowest risk?

• Generic reformulation with a materially different preservative system and viscosity profile, combined with a label carve-out from disputed dosing schedules
• Launch after patent expiration with no remaining “listed” protection
• Successful design-around based on particle size and manufacturing method changes that avoid claim scope

How do preservative-free and device changes affect the patent landscape?

Featured snippet answer: Preservative-free and unit-dose formats are a recurring source of secondary patent coverage because they require separate formulation and container/pick-and-place handling.

Typical IP hooks for preservative-free drops

• Composition patents for preservative-free suspensions (stabilizer selection)
• Sterility assurance process and packaging integrity specs
• Device and container patent claims tied to compatibility and dosing accuracy

What does this do to competition?

It creates “product differentiation” that can justify delayed generic uptake even when the active ingredient is generic. Payer preference and patient tolerability matter for how much of this segment is willing to pay premiums.

What method-of-use patents can block label-aligned generic competition?

Featured snippet answer: Method-of-use patents can block or complicate generic entry when the generic’s proposed label mirrors the patented regimen or when the label cannot carve out the patented dosing/taper schedule without losing commercial utility.

What to watch in label negotiations

• Indication language differences (for example, postoperative inflammation phrasing)
• Dosing frequency and taper wording
• Population qualifiers that map to method-of-use claims

In practice, the most litigated method-of-use assertions are those that are hard to carve out without substantially changing the intended use.

How does ATC S01BA compare with other ophthalmic steroid categories (combination products)?

Featured snippet answer: The main competitive cross-over is between plain steroids (S01BA) and steroid combination classes; however, patent enforcement focus differs because combinations bring additional composition-of-matter and method-of-use constraints for both drug components.

Why “plain” categories still face combination-like complexities

Even though S01BA excludes steroid-antibiotic products at the ATC coding level, companies still patent:

• excipient systems
• stabilization strategies
• viscosity and residence-time improvements

So, the generic barrier is not just the presence or absence of antibiotics; it is the formulation architecture.

Key takeaways

• S01BA “plain corticosteroids” have mature base molecules but ongoing secondary patent coverage in formulations, particle-size specs, and dosing/device variants.
• Market entry risk is highest when generic applicants match strength, preservative system, and suspension characteristics to branded specifications and when proposed labels align with asserted method-of-use regimens.
• Competitive dynamics favor generics on cost, but preservative-free and unit-dose innovations can sustain brand advantage via new secondary patent families.
• The enforceable patent map is molecule- and NDA-specific; ATC-level screening mainly informs where to allocate due diligence resources (formulation vs method-of-use vs packaging).

FAQs

1) What patent types most commonly survive after active-drug composition-of-matter expiry in ophthalmic plain corticosteroids?
Secondary formulation composition, particle/solid-state, and manufacturing-process patents usually persist, with method-of-use patents asserted when label alignment is difficult to carve out.

2) Do preservative-free versions of plain ophthalmic corticosteroids typically have separate patent estates?
Yes. Preservative-free suspensions and unit-dose packaging commonly add formulation and container/sterility-related protection that can be independent of the preserved product’s estate.

3) How does a generic ANDA paragraph IV filing change the timing of S01BA product launches in the U.S.?
It triggers litigation-driven stays tied to Orange Book-listed patents; settlement often trades for delayed launch dates and label carve-outs.

4) What label elements most often determine infringement risk for method-of-use patents in S01BA?
Indication phrasing, dosing frequency, and taper language that track the asserted regimen.

5) Are SPCs and national patents the main barrier to generics for plain ophthalmic corticosteroids in Europe?
Often yes, especially when SPCs extend protection for specific marketing authorizations; reformulations with distinct authorizations can create follow-on rights.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Paragraph IV Certification and Notice of Certifications. U.S. Food and Drug Administration.
3. European Medicines Agency. Supplementary Protection Certificate (SPC) guidance and related EMA frameworks. European Medicines Agency.